**Amendments to the claims:**

~~Claims:~~
What is claimed is:

1. (Original) Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterised in that it:
(i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or
(ii) has a melting point above 145°C and/or
(iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 $cm^{-1}$; and/or
(iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or
(v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II.

2. (Original) A compound according to claim 1, which comprises from 1.8 to 2.3 or 1.9 to 2.1 molar equivalents of water.

3. (Currently Amended) A compound according to claim 1 ~~or claim 2~~, which comprises 2.0 molar equivalents.

4. (Currently Amended) A compound according to ~~any one of claims 1 to 3~~ claim 1, which has a melting point in the range of from 150°C to 154°C.

5. (Currently Amended) A compound according to ~~any one of claims 1 to 4~~ claim 1, which has a melting point of
150°C, 151°C, 152°C, 153°C or 154°C.

6. (Currently Amended) A compound according to ~~any one of claims 1 to 5~~ claim 1, which provides an infra red spectrum containing peaks at 3510, 3342, 3307, 3076, 1665, 1632, 1598, 1548, 1520, 1343, 1330, 1310, 1267, 1240, 1216, 1162, 1147, 1119, 1105, 1048, 1036, 1025, 981, 921, 891, 873, 854, 801, 767, 720, 626, 573, 553 and 500 $cm^{-1}$.

7. (Currently Amended) A compound according to ~~any one of claims 1 to 6~~ claim 1, which provides an infra red spectrum substantially as illustrated in Figure (I).

8. (Original) A process for preparing hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride according to claim 1, characterised in that N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, is hydrated in the presence of the required amount of water.

9. (Original) A process according to claim 8, wherein the Hydrochloride is crystallised or recrystallised from water or an aqueous solvent.

10. (Currently Amended) A pharmaceutical composition comprising ~~Compound (I)~~ the compound according to claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier.

Claims 11-13 (Cancelled).

14. (Currenlty Amended) A method for the treatment and/or prophylaxis of arrhythmia and ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of ~~Compound (I)~~ the compound acording to claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human mammal in need thereof.